Under the title, What’s Next in Psoriasis? From Maintenance to Disease Modification, the 2022 IPC Think Tank scientific symposium was held on Friday, December 9th, in Miami, Florida. Read the full report or a summary of the five psoriasis focused sessions.
Recurrent flares, painful fiery-red skin, and sterile pustules — are the characteristics of Generalized Pustular Psoriasis (GPP), a rare and potentially life-threatening autoinflammatory disease.
Biologics and biosimilars have created many new options in psoriasis treatment for patients worldwide, but patients worldwide face barriers to acquiring them. This has led IPC Councilor Dr. Matias Maskin to reconsider what success means for psoriasis patients.
The monkeypox outbreak has had a significant impact all across the globe. Here’s what to know about monkeypox symptoms, treatment, and prevention.
The European Academy of Dermatology and Venereology (EADV) organized its 31st congress in Milano, Italy, under the parole “Designing the Future of Dermatology and Venereology.” The event took place from September 7 – 10, 2022, as a hybrid meeting with the option of attending virtually or in person. The following congress report includes fifteen summaries of presentations focusing on psoriasis. You can download the full report or read the summary.
Psoriasis and tuberculosis have long gone hand-in-hand. This is especially true in certain parts of the world, where latent tuberculosis continues to be widespread. With one-quarter of the global population estimated to have latent tuberculosis, guidelines to properly screen for and treat tuberculosis in psoriasis patients are critical.
Prof. Christine Bundy shares how clinicians can center mental health in psoriasis care — and what to look out for in your patients.
Personalized care has become increasingly utilized in the past two few decades, evolving as we have gained a greater understanding of the human genome and recognized the importance of shifting away from a “one size fits all” approach to medicine.
Patients with psoriasis are at increased risk for cardiovascular disease —and lack of physical activity may be a driving cause.
Sotyktu™(deucravacitinib), an oral treatment for adults with moderate to severe plaque psoriasis. Sotyktu™ is the only approved TYK2 inhibitor worldwide and the first improvement in oral treatment for moderate to severe plaque psoriasis in nearly ten years.
The 7th Congress of the Skin Inflammation & Psoriasis International Network (SPIN) was held Wednesday, July 6 – Friday, July 8, 2022, in Paris, France. The following congress report includes twelve summaries of presentations focusing on psoriasis. You can download the full report or read on for a brief look at some of the highlights.
Claro, a digital platform built to improve mental health for those with psoriasis who are living in Spain, the United Kingdom, and Italy.
